



**COLORADO**

Department of Health Care  
Policy & Financing

**AGENDA**  
**Pharmaceutics & Therapeutics Committee**  
**Department of Health Care Policy & Financing**

Zoom Webinar Registration:

[https://primetherapeutics.zoom.us/webinar/register/WN\\_P30waLhbRjalokf1B4C53w](https://primetherapeutics.zoom.us/webinar/register/WN_P30waLhbRjalokf1B4C53w)

Tuesday, January 07, 2025, 1:00-5:00 P.M.

## **1. Committee Member Introductions**

Introduction of New Members

Vote for Committee Positions - Chairperson, Vice Chairperson

## **2. Unfinished Business and General Orders**

Approval of minutes from October 8, 2024 P&T meeting

Updates from October 8, 2024 P&T Meeting

## **3. New Business**

Updates from the Prior Authorization Call Center

## **4. Drug Classes Up for Review**

- Review of Non-Opioid Analgesia Agents - Oral & Topical -
- Review of Opioids - Short-Acting, Long-Acting
- Review of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) - Oral & Non-Oral
- Review of Anticonvulsants, Oral
- Review of Anti-Parkinson's Agents
- Review of Newer Generation Antidepressants
- Review of Atypical Antipsychotics - Oral/Topical
- Review of Calcitonin Gene-Related Peptide Inhibitors (CGRPIs)
- Review of Stimulants and Related Agents

Mass review drug classes:

- Opioids, Fentanyl Preparations
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants (TCAs)
- Benzodiazepines (Non-Sedative Hypnotic)
- Anxiolytics, Non-Benzodiazepine
- Lithium Agents
- Neurocognitive Disorder Agents
- Sedative Hypnotics

Improving health care equity, access, and outcomes for the people we serve while  
saving Coloradans money on health care and driving value for Colorado.

[www.colorado.gov/hcpf](http://www.colorado.gov/hcpf)



- Skeletal Muscle Relaxants
- Triptans, Ditans and Other Migraine Treatments - Oral & Non-Oral
- Multiple Sclerosis Therapies - Disease Modifying & Symptom Management
- Ophthalmics, Allergy
- Ophthalmics, Immunomodulators
- Ophthalmics, Anti-Inflammatories
- Ophthalmics, Glaucoma
- Ophthalmics, Allergy

Each Review will contain:

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share overview
- Committee Discussion and Recommendations for each Class

Mass Review drug classes will only include:

- Overview for each Drug Class, including market share overview

Presentations:

- Interested parties who want to present at the meeting shall give advanced notice and provide a one-page summary of the clinical testimony that will be presented for P&T Committee dissemination.
- Advance notice requests to present and/or written public comments can be submitted to Jessica Czechowski, Director - Clinical Account Services, [Jessica.Czechowski@primetherapeutics.com](mailto:Jessica.Czechowski@primetherapeutics.com) and carbon copy: Greg Miller, PDL & Clinical Strategy Pharmacist, [greg.l.miller@state.co.us](mailto:greg.l.miller@state.co.us). Once approved, public comments will be distributed to P&T Committee Members.
- Requests and public comment summaries are due by **December 31, 2024 by 5pm MST**.

## 5. Adjourn

Upcoming Meeting Date: April 8, 2025.

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the [504/ADA Coordinator](#) or [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.

